

MIT Open Access Articles

The Role of Epigenetic Mechanisms in the Regulation of Gene Expression in the Nervous System

The MIT Faculty has made this article openly available. **Please share** how this access benefits you. Your story matters.

Citation: Cholewa-Waclaw, Justyna; Bird, Adrian; von Schimmelmann, Melanie; Schaefer, Anne; Yu, Huimei; Song, Hongjun; Madabhushi, Ram and Tsai, Li-Huei. "The Role of Epigenetic Mechanisms in the Regulation of Gene Expression in the Nervous System." *The Journal of Neuroscience* 36, no. 45 (November 2016): 11427–11434 © 2016 The Authors

As Published: <http://dx.doi.org/10.1523/JNEUROSCI.2492-16.2016>

Publisher: Society for Neuroscience

Persistent URL: <http://hdl.handle.net/1721.1/109955>

Version: Final published version: final published article, as it appeared in a journal, conference proceedings, or other formally published context

Terms of use: Creative Commons Attribution 4.0 International License



Symposium

The Role of Epigenetic Mechanisms in the Regulation of Gene Expression in the Nervous System

Justyna Cholewa-Waclaw,¹  Adrian Bird,¹ Melanie von Schimmelmann,² Anne Schaefer,² Huimei Yu,³ Hongjun Song,³ Ram Madabhushi,⁴ and Li-Huei Tsai⁴

¹Wellcome Trust Centre for Cell Biology, University of Edinburgh, Edinburgh EH9 3BF, United Kingdom, ²Friedman Brain Institute, Icahn School of Medicine at Mount Sinai, New York, New York 10029, ³Institute for Cell Engineering, Department of Neurology, and the Solomon H. Snyder Department of Neuroscience, Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, and ⁴Picower Institute for Learning and Memory and Department of Brain and Cognitive Sciences, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139

Neuroepigenetics is a newly emerging field in neurobiology that addresses the epigenetic mechanism of gene expression regulation in various postmitotic neurons, both over time and in response to environmental stimuli. In addition to its fundamental contribution to our understanding of basic neuronal physiology, alterations in these neuroepigenetic mechanisms have been recently linked to numerous neurodevelopmental, psychiatric, and neurodegenerative disorders. This article provides a selective review of the role of DNA and histone modifications in neuronal signal-induced gene expression regulation, plasticity, and survival and how targeting these mechanisms could advance the development of future therapies. In addition, we discuss a recent discovery on how double-strand breaks of genomic DNA mediate the rapid induction of activity-dependent gene expression in neurons.

Key words: DNA double strand breaks; DNA methylation; MeCP2; polycomb repressive complex; topoisomerase II

Introduction

Organs, including the brain, are determined by the pattern of gene expression that emerges in each cell lineage during development. The key drivers of these genetic programs are proteins that recognize specific combinations of nucleotides that specify a genomic address. By binding to their sites, either alone or in conjunction with others, these sequence-specific DNA binding proteins or “transcription factors” determine which genes are actively expressed and which must remain silent. Several lines of evidence suggest, however, that there are more constraints on development and differentiation than simply the availability of transcription factors. For example, although cells of the liver, skin, intestine, etc., possess the entire genome, it took many years to find ways of converting a differentiated cell into a stem cell that could once again give rise to the whole organism. Even now, reversal of differentiation is still a highly inefficient process. A likely reason is that “epigenetic marking” of the genome, laid down during the developmental history of the cell, “conditions” the genome’s response to transcription factors and is therefore an

essential additional factor in determining programs of gene expression. “Epigenetics” refers to the study of ways in which chromosome regions adapt structurally so as to register, signal, or perpetuate local activity states (Bird, 2007).

A key feature of epigenetic marking is that it is stable, sometimes across cell generations, but also reversible. It is mediated by proteins that add, remove, or interpret the modified structures, referred to as “writers,” “erasers,” and “readers” respectively. Epigenetic systems include DNA methylation (Bird, 2002), and the polycomb/trithorax system (Francis and Kingston, 2001). Other epigenetic mechanisms involve RNA (Vaistij et al., 2002; Volpe et al., 2002) or the silencing or activation of genes due to their localization within the nucleus (Brown et al., 1997; Mahy et al., 2002). These and other processes appear to be closely interwoven with histone modification, which is itself a diverse, complex system of chromosome marking (Jenuwein and Allis, 2001). Histone proteins stably associate with DNA to form a repeating structural unit that organizes the genome. The combination of DNA and periodic histone complexes is referred to as chromatin, resembling beads on a string of DNA. In addition to their structural role, histones possess exposed tails that can be marked by chemical modification. For example, acetylation of histone tails by histone acetyltransferases loosens the contact with DNA and also creates binding sites for protein readers that facilitate gene expression. Acetylation is removed by histone deacetylase-containing complexes, which therefore inhibit the activity of genes. Methylation of histone tails can be either activating or repressive, depending on the precise amino acid that is affected. For example, the function of the Polycomb Repressive Complex 2 (PRC2) is mediated by its enzymatic components Ezh1 and Ezh2, which catalyze methylation of lysine 27 on histone H3 leading to gene silencing (Müller et al., 2002). There is evidence that PRC2 is essential in developing neu-

Received July 26, 2016; revised Aug. 29, 2016; accepted Aug. 31, 2016.

Work in the A.B. laboratory was supported by Rett Syndrome Research Trust Consortium Grant and Wellcome Trust Programme Grant 091580. Work in the H.S. laboratory was supported by National Institutes of Health Grants R37NS047344, U19MH106434, and P01NS097206. Work in the A.S. laboratory was supported by the National Institutes of Health Director New Innovator Award DP2 MH100012-01 to A.S., 1R01 NS091574-01A1 to A.S., CURE Challenge Award to A.S., and National Alliance for Research on Schizophrenia and Depression Young Investigator Award 22802 to M.v.S. Work in the L.-H.T. laboratory was supported by the Glenn Foundation and the Belfer Neurodegeneration Consortium Grants.

The authors declare no competing financial interests.

Correspondence should be addressed to Dr. Li-Huei Tsai, 77 Massachusetts Avenue, Building 46, Room 4235A, Cambridge, MA 02139. E-mail: lhstai@mit.edu.

DOI:10.1523/JNEUROSCI.2492-16.2016

Copyright © 2016 the authors 0270-6474/16/3611427-08\$15.00/0

rons to prevent the expression of inappropriate (e.g., non-neuronal) genes (Hirabayashi et al., 2009; Pereira et al., 2010). A prevalent epigenetic mark that directly targets DNA is methylation of the 5-position of cytosine (5mC) (Jaenisch and Bird, 2003). It is deposited predominantly at CpG sites by DNA methyltransferases DNMT3a and DNMT3b and maintained in dividing cells by DNMT1. Mapping of DNA methylation in the brain has uncovered unexpected differences compared with other somatic tissues, including unprecedentedly high levels of non-CpG methylation (Lister et al., 2013; Guo et al., 2014) and also of the oxidized form of 5mC, 5-hydroxymethylcytosine.

The importance of epigenetic systems in disease has become increasingly apparent with the introduction of genome sequencing as a diagnostic tool, as mutations that affect epigenetic readers, writers, or erasers are often implicated in cases of intellectual disability (Bjornsson, 2015). These discoveries have shone a spotlight on the role of epigenetic processes in the brain, about which we still have much to learn. Here we review aspects of this rapidly expanding field. Because of space constraints, we have not attempted a comprehensive review but focus on specific areas of current activity. We discuss evidence that DNA methylation dynamics contributes to neuronal diversity and plasticity, and we also review progress in understanding how mutations affecting a DNA methylation reader, MeCP2, give rise to the neurological disorder Rett syndrome (RTT). Transcriptional repression by the polycomb complex is prevalent in the brain, and we summarize recent evidence implicating this system in silencing of genes whose expression leads to neurodegeneration in adults. Finally, we discuss a novel phenomenon that is implicated in neuronal function: the formation of double-stranded breaks (DSBs) at regulatory regions of a subset of genes that are activated when neurons fire. Through these exemplar discoveries, we hope to convey the excitement and rapid progress now associated with the burgeoning field of neuroepigenetics.

Dynamic DNA modifications in neurons and their functions

It was believed for decades that cytosine methylation in the genomic DNA of terminally differentiated cells is largely irreversible (Ooi and Bestor, 2008). Only recently have several advances in the neuroscience field collectively helped to overturn the dogma and started to reveal functional roles of dynamic DNA demethylation in neurons (Martinowich et al., 2003; Miller and Sweatt, 2007; Nelson et al., 2008; Ma et al., 2009; Feng et al., 2010, 2015; Guo et al., 2011b, c; Kaas et al., 2013; Lister et al., 2013; Rudenko et al., 2013; Meadows et al., 2015; Yu et al., 2015; Yao et al., 2016).

First, studies have convincingly demonstrated dynamic changes of DNA methylation levels in postmitotic neurons. Because of the complexity of the mammalian brain consisting of many cell types and each cell type exhibiting a distinct methylome, it has been challenging to demonstrate robust methylation changes in a particular cell type using gold standard approaches used in the epigenetic field, such as bisulfite sequencing (Shin et al., 2014). Culture studies showed that depolarization of neurons leads to significant decrease of methylation levels at the promoter IV region of the *brain-derived neurotrophic factor* (*Bdnf*) (Martinowich et al., 2003). Using a relative pure population of dentate granule neurons in the adult mouse hippocampus that can be easily switched from an inactive state to an active state by electroconvulsive stimulation, it was shown that neuronal activation leads to demethylation at promoter IX region of *Bdnf* gene (Ma et al., 2009). Subsequent genome-wide analysis further revealed large scale modification of the neuronal methylation landscape

by neuronal activation (Guo et al., 2011c). Approximately 1% of CpG sites examined exhibit methylation changes within 4 h, including both *de novo* methylation and demethylation. Notably, physiological stimulation, such as running, also leads to similar dynamic methylation changes. Dynamic DNA methylation in neurons mostly occurs in low CpG density regions and intergenic regions. More recently, genetic approaches have been developed to facilitate nuclear isolation from different neuronal subtypes of adult mouse brain and set the stage for future studies of changes in cell-type specific DNA methylation dynamics in response to behavioral stimulations for epigenetic analysis (Mo et al., 2015).

Second, the molecular machinery mediating active DNA demethylation has been recently identified (Guo et al., 2011a). Accompanying the rediscovery of another DNA modification, 5-hydroxymethylcytosine (5hmC), in adult mouse neurons (Kriaucionis and Heintz, 2009), Tet proteins were identified to oxidize 5mC to 5hmC (Tahiliani et al., 2009; Ito et al., 2010). These findings immediately raised the possibility that Tet proteins initiate the active DNA demethylation process via the 5hmC intermediate step. Indeed, evidence from dentate granule neurons *in vivo* provided the first support of this model and further showed that Tet-initiated active DNA demethylation is mediated by 5hmC deamination followed by a base-excision repair mechanism (Guo et al., 2011b). Later studies revealed that Tet proteins can also further oxidize 5hmC sequentially into 5fC and then 5CaC, both of which can be converted to unmethylated cytosine via a TDG-mediated base-excision repair mechanism (Wu and Zhang, 2014).

Third, identification of the molecular machinery mediating active DNA demethylation provides essential tools, for the first time, to directly address the physiological role of active DNA demethylation in neuronal functions at cellular, circuitry, and behavioral levels. Not surprisingly, dysregulation of TET functions leads to deficits in neural stem cells and their differentiation (Zhang et al., 2013). In addition, genetic manipulation of Tet functions provides evidence for a causal role of DNA demethylation in memory formation and extinction as well as drug addiction (Kaas et al., 2013; Rudenko et al., 2013; Feng et al., 2015). At the cellular level, Tet3 regulates glutamatergic synaptic transmission by controlling the surface expression of glutamate receptors (Yu et al., 2015). Notably, Tet3 expression in neurons is bidirectionally regulated by systemic circuitry activity, as reducing network firing leads to decreased Tet3 expression, whereas elevating network activity results in increased Tet3 expression. Global changes in neuronal network firing induce synaptic scaling, a form of homeostatic synaptic plasticity that affects all synapses within a neurons (Turriano, 2008). Interestingly, dysregulation of Tet3-mediated DNA demethylation signaling prevents both synaptic scaling-up and scaling-down (Yu et al., 2015). These studies identify Tet3 as a novel global synaptic activity sensor and suggest that even the most fundamental properties of neurons, such as synaptic transmission and surface GluR1 levels, are dynamically regulated by DNA demethylation via DNA oxidation and subsequent base-excision repair. Together with the recent finding that neuronal activity-triggered formation of DNA DSBs on promoters of early-response genes controls their expression in neurons (Madabhushi et al., 2015), these results suggest a previously underappreciated role for DNA repair in normal neuronal physiology and plasticity. Interestingly, blocking of *de novo* DNA demethylation by pharmacological inhibition of DNMTs also affects synaptic scaling (Meadows et al., 2015), suggesting a critical role of dynamic DNA methylation levels in homeostatic plasticity.

The recent several years have witnessed tremendous progress in our understanding of DNA methylation in neurons. First,




Figure 1. Understanding MeCP2 function. **A**, MeCP2 binds to chromosomes at sites of DNA methylation, which are absent at CpG island promoters, but present in gene bodies and intergenic regions of the genome. **B**, Missense mutations that cause RTT are concentrated in the MBD and NID of MeCP2. Missense mutations in the population at large avoid these domains.

many more forms of DNA modifications have been identified in neurons. In addition to oxidation production of 5mC, including 5hmC, 5fC, and 5CaC, single-based genome-wide studies have revealed enrichment of DNA methylation in the non-CpG context in neurons and suggested their role in suppressing gene expression (Lister et al., 2013; Guo et al., 2014). Intriguingly, non-CpG methylation appears to correlate even better with gene expression than CpG methylation (Lister et al., 2013; Guo et al., 2014; Mo et al., 2015). More recently, N(6)-methyladenine (N6mA), another form of DNA modification, was identified in the mammalian genome (Wu et al., 2016). Second, large-scale profiling of different forms of DNA modifications has revealed dynamic nature of different types of neuronal methylation landscape during development and in response to different stimuli. Third, emerging evidence converges and suggests that DNA methylation in neurons largely suppresses gene expression, whereas dynamic changes in DNA methylation play a critical role in meta-plasticity, a phenomenon in which the history of a neuron's activity determines its current state and its ability to undergo synaptic plasticity (Abraham and Bear, 1996). Given the new tools and rapid development of the field, new principles are likely to emerge soon.

MeCP2: how loss of a DNA methylation reader affects the brain

A long-known DNA methylation reader is Methyl-CpG binding Protein 2 (MeCP2), which binds specifically to 5-methylcytosine in a mCG or mCA contexts. The protein binds to chromosomes in a DNA methylation-dependent manner (Fig. 1A) and is most highly expressed in neurons, where it approaches the abundance of histones. MeCP2 behaves as a transcriptional repressor that binds methylated DNA and recruits the multiprotein corepressor NCoR, which removes acetyl groups from histones. Importantly, mutations in the *MECP2* gene are the almost exclusive cause of a neurological disorder called RTT, which manifests as loss of acquired language and motor skills, seizures, mental retardation, and autistic behaviors. RTT is of particular interest as a monogenic disorder caused by effective loss of an epigenetic reader that is essential for brain function. Moreover, convincing animal models closely mimic the human disorder. As the *MECP2* gene is on the X chromosome (Amir et al., 1999), RTT occurs almost exclusively in girls, who typically develop normally for 6–18 months and then regress. Males who are hemizygous for these

mutations rarely survive infancy. Having the correct amount of MeCP2 in neurons is clearly critical, as abnormally high levels due to duplication of the *MECP2* gene also result in severe intellectual disability (Collins et al., 2004; Luikenhuis et al., 2004). It seems that a high, but balanced, concentration of MeCP2 is crucial for neurons to operate properly. Both RTT and *MECP2* overexpression syndrome phenotypes are reversible in mice (Guy et al., 2007; Sztainberg et al., 2015), indicating that neurons are not permanently damaged by development with too little or too much of the protein and raising the possibility that these conditions will be curable in humans, too.

Significant progress has been made in understanding the molecular basis of MeCP2-related disorders (Lyst and Bird,

2015). Numerous different mutations have been reported in the *MECP2* gene of patients with RTT, providing an important resource that pinpoints crucial protein domains (Fig. 1B). Analysis of missense mutations, which alter only one amino acid, reveals a strikingly nonrandom distribution (Lyst et al., 2013). Mutations cluster into two discrete regions that coincide with domains mediating protein-protein or protein-DNA interactions. Closest to the N terminus is the Methyl-CpG Binding Domain (MBD) and mutations interfere with DNA binding and often destabilize the protein (Nan et al., 1993). The second domain is the NCoR Interaction Domain (NID), which has been shown to bind the histone deacetylase complex NCoR (Lyst et al., 2013). The importance of these two domains is underlined by the finding that missense mutations occurring in the human population at large (neutral variants) occur throughout the length of the protein, yet are largely excluded from these two sensitive regions (Fig. 1B). These observations suggest that MeCP2 functions as a “bridge” between methylated DNA and the corepressor complex, with breakage of either end of the bridge resulting in RTT. As other roles for MeCP2 have also been proposed, including transcriptional activation, alternative splicing, maintenance of global structure of chromatin, regulation of protein synthesis, or combinations of these functions (Lyst and Bird, 2015), it is now vital to critically test the bridge hypothesis.

The role of MeCP2 in transcriptional regulation is hotly debated. Some evidence suggests that the protein activates transcription (Chahrouh et al., 2008; Li et al., 2013), whereas other experimental results support a repressive role. In favor of a repressor model, the primary target sequence, methyl-CpG, is a repressive signal in a variety of systems and MeCP2 colocalizes in mouse cell nuclei with heavily methylated foci that are “heterochromatic” and therefore transcriptionally silent. Moreover, the association between MeCP2 and HDAC-containing corepressor complexes, including NCoR and Sin3a, is closely correlated with its ability to repress transcription in cell-based assays (Nan et al., 1997, 1998; Lyst et al., 2013). Mutations that preclude binding to NCoR, or treatment with inhibitors of the histone deacetylases upon which these corepressors depend, abolish MeCP2-dependent gene silencing. It is also reported that depletion of MeCP2 increases chromatin acetylation levels *in vivo* and elevates expression of normally silenced DNA repeat elements and retrotransposons (Skene et al., 2010). High levels of the methylated sequence mCA, recently discovered in brain (Guo et al., 2014), do

not alter this picture, as this modified sequence also appears to behave as a repressive signal. Methylated CA accumulates in the mouse brain postnatally, coincident with the increase in MeCP2 abundance, and MeCP2 binds to mCA as well as mCG (Gabel et al., 2015). Specifically, MeCP2 has been found to regulate transcription of long genes in the brain and its loss causes their upregulation, particularly those that are mCA-enriched (Gabel et al., 2015). Unlike the repressor model, for which candidate partners have been identified, the activating effect of MeCP2 is not well understood. Deficiency of MeCP2 evidently leads to smaller neurons with less RNA (Yazdani et al., 2012; Li et al., 2013), but whether this effect is direct or indirect is unknown, as are the molecular mechanisms that might be involved. A proposal that MeCP2 may activate through binding to hydroxymethylcytosine (Mellén et al., 2012) has been questioned, as the great majority of hmC is in the dinucleotide sequence hmCG, which does not bind MeCP2 (Valinluck et al., 2004; Gabel et al., 2015). It is reported, however, that non-CG methylation is associated with both upregulation and downregulation of gene expression by MeCP2 (Chen et al., 2015). Despite some remaining uncertainty regarding the function of MeCP2, there are grounds for optimism that recent experimental and technological advances have begun to illuminate its fundamental role in the brain. In time, these advances promise to facilitate the search for therapies for *MECP2*-related disorders.

PRC2 protects neurons against neurodegeneration

Normal brain function critically depends on the interaction between the highly specialized neurons. A failure to maintain neuronal specification in the adult brain is commonly associated with aging and age-related neurodegenerative disorders, including Huntington's and Alzheimer's disease. Alterations in neuron type-specific gene expression in medium spiny neurons (MSNs) in the striatum, for example, represents one of the earliest signs of Huntington's disease (HD) pathology, preceding neuronal dysfunction, cell death, and behavioral alterations (Zabel et al., 2009). These findings suggest a possible link between the fidelity of neuronal transcriptional specification and neuronal survival in the adult brain.

Neuronal specification is governed by transcriptional programs that are established during the early stages of neuronal development (Molyneaux et al., 2007; Hobert, 2011) and remain in place in the adult brain (Deneris and Hobert, 2014). Programs of gene activation by transcription factors are combined with systems that suppress genes whose expression might enforce the differentiation of neurons of other types (Cobos et al., 2006; Molyneaux et al., 2007; Hobert, 2011, 2016; Greig et al., 2013; Deneris and Hobert, 2014). Gene regulatory processes that play a pivotal role in neuronal specification include the epigenetic silencing of non-neuronal/other neuron fate-determining genes. Much of the negative gene regulation in developing neurons is achieved by the PRC2 (Hirabayashi et al., 2009; Pereira et al., 2010; Di Meglio et al., 2013; Corley and Kroll, 2015; Zemke et al., 2015). While tremendous progress has been made in elucidating the role of PRC2 in neuronal specification during development (Corley and Kroll, 2015), little is known about the role of PRC2 in the adult brain. Recent data highlight the role of PRC2 in the prevention of systemic neurodegeneration, as PRC2 contributes to the selective suppression of a transcription program that is detrimental for adult neuron function and survival (von Schimmelmänn, 2016). More than 2000 PRC2 target genes that are associated with high levels of the methylated histone H3K27me3 at their TSS have been identified. Surprisingly, many of these transcriptionally silent genes at which H3K27me3 and PRC2 colocalize, are also associated

with the transcriptionally activating H3K4me3 chromatin modification (von Schimmelmänn, 2016). In ES cells as well as in cells of other types, the combination of H3K27me3 and H3K4me3 at promoters is referred to as chromatin "bivalency" and supports the plasticity of cell differentiation (Barski et al., 2007; Mohn et al., 2008; Dobenecker et al., 2015). It remains unclear, however, if or how fully differentiated neurons could benefit from the bivalent state. The results suggest that, whereas the majority of H3K27me3 target genes in MSNs are surprisingly insensitive to PRC2 deficiency, PRC2 selectively controls the transcriptional silencing of these bivalent genes in adult neurons (von Schimmelmänn, 2016). Indeed, PRC2 deficiency in adult MSNs leads to the derepression of a specific group of bivalent PRC2 target genes that are dominated by self-regulating transcription factors, as well as several death-promoting genes normally suppressed in these neurons. The majority of the PRC2-suppressed genes encode transcription factors that are associated with the transcriptional specification of other cell and neuron types (von Schimmelmänn, 2016). The data suggest that these transcription factors may become expressed at relatively high levels due to their ability to form autoregulatory and coregulatory transcriptional network(s) that reinforce their own expression. Therefore, the formation of mutually reinforced transcription loops among PRC2 target genes represents a possible mechanism for the selective and progressive upregulation of PRC2 target genes. The upregulation of non-MSN-specific transcriptional regulators in PRC2-deficient MSNs, however, does not lead to the expected neuronal dedifferentiation or induction of other neuron type-specific gene programs (i.e., of dopaminergic neurons or Purkinje cells) but is associated with the subsequent downregulation of highly expressed MSN-specific genes (von Schimmelmänn, 2016). These age-dependent transcriptional changes in PRC2-deficient neurons are associated with the development of progressive and fatal neurodegeneration in mice. Moreover, the molecular, cellular, and behavioral changes associated with postnatal neuron-specific PRC2 deficiency overlap with the neurodegenerative phenotypes observed in mice with HD, giving credence to the potential contribution of epigenetic mechanisms, particularly to PRC2-mediated gene expression regulation, in HD pathology and possibly in other neurodegenerative processes.

In summary, current data reveal that PRC2 links the maintenance of adult neuron specification to neuronal survival (von Schimmelmänn, 2016). Altered neuron specification may interfere with coordinated function of neuronal networks and may be harmful for overall brain function. It is plausible that neurons possess an intrinsic mechanism that triggers the elimination of neurons with defective specification during development. It is moreover tempting to speculate that the activation of the PRC2-controlled transcriptional network, including the death-promoting genes, may represent a type of checkpoint mechanism that enables the elimination of neurons with impaired PRC2 function in the adult brain. Changes in PRC2 function could be triggered either transiently, by nonpersisting events such as seizures (Reynolds et al., 2015) or chronic stress, or permanently, by the expression of pathogenic proteins such as mutant huntingtin protein, which can directly interfere with PRC2 recruitment and function (Seong et al., 2010; Dong et al., 2015). While short-term activation of such a mechanism could be beneficial for ensuring brain integrity, it seems that persistent changes in the activity or recruitment of PRC2, as well as other H3K27me3-controlling enzymes, may lead to systemic neurodegeneration. It is proposed that PRC2 is essential for the protection of neurons from neurodegeneration by the selective suppression of a self-enforcing transcriptional network that, once initiated, can set neurons on an irreversible path of neurodegeneration.

The role of activity-induced DNA breaks in neuronal physiology and disease

Our behavior is remarkably shaped by our experiences. The ability of experience to influence the development of long-lasting adaptive responses requires an intricate “dialogue between genes and synapses” in which an incoming stimulus activates signaling cascades in neurons that culminates in new protein synthesis and the activation of new gene transcription programs (Kandel, 2001). The earliest genes to be induced in this program are the early response genes, and these are enriched for transcription factors, such as *Fos*, *Npas4*, *Nr4a1*, and *Egr1*. These transcription factors, in turn, prime the expression of the so-called late response genes, such as *Bdnf* and *Cpg15*, and together these immediate early gene products ultimately regulate experience-driven changes to synapses, learning, and memory (West and Greenberg, 2011). A great body of research conducted over the past 30 years has provided crucial insights into the mechanisms that govern the rapid induction of these immediate early genes (West and Greenberg, 2011). Despite these details, the precise mechanisms that constrain early response genes in the absence of a stimulus, and those that trigger their rapid induction, remain poorly understood.

An important recent finding in this regard has been the observation that numerous paradigms of neuronal stimulation, including exposure of mice to physiological learning behaviors *in vivo*, result in the formation of DNA double-strand breaks (DSBs) (Suberbielle et al., 2013; Madabhushi et al., 2015). These neuronal activity-induced DSBs are restricted to only handful of loci in the genome, and these loci are also enriched for the early response genes, including *Fos*, *Npas4*, *Egr1*, and *Nr4a1* (Madabhushi et al., 2015). Attempts to understand the mechanisms underlying this phenomenon have revealed that neural activity-induced DNA breaks are generated by a Type II topoisomerase, Topo II β , and these Topo II β -mediated DSBs are essential for the rapid induction of early response genes. While *Top2b* knockdown attenuates both activity-induced DSB formation and early response gene induction, engineering targeted DSBs in the promoters of early response genes allows for the induction of these early response genes even when *Top2b* is knocked down (Madabhushi et al., 2015). Together, these results reveal DSB formation as a novel triggering mechanism for the induction of early response genes following neuronal activity.

While these mechanisms were tested in neurons, a recent report demonstrated that stimulation of proliferating cells with serum also results in Topo II β -mediated DSB formation and γ H2AX accumulation at immediate early genes, including *Fos* and *Egr1* (Bunch et al., 2015). Inhibition of Topo II β activity increases RNAPII pausing at these genes (Bunch et al., 2015). In addition to this, Topo II β -mediated DSBs have been shown to induce gene expression in other cell types in response to stimulation by androgens, estrogen, and insulin (Ju et al., 2006; Wong et al., 2009). Together, these studies suggest that activity-induced DSB formation by Topo II β might be a conserved mechanism to rapidly induce gene expression.

The precise mechanisms by which activity-induced DSBs facilitate gene expression also remain poorly understood. Interestingly, an analysis of motifs that were enriched at Topo II β binding sites in neurons revealed that the binding motif of the architectural protein, CTCF, was the most significantly enriched at these sites (Madabhushi et al., 2015). The enrichment of CTCF at Topo II β binding sites and the sites of activity-induced DSBs suggest an intriguing model in which CTCF-mediated chromatin looping imposes a topological constraint that precludes early re-




Figure 2. Activity-induced DNA breaks “switch-on” gene expression. Left, IEGs are important for synaptic plasticity in the brain and are “switched off” under basal conditions due to the presence of topological constraints. Right, Neuronal activity triggers the formation of Topo II β -mediated DNA breaks in the promoters of a subset of IEGs, which overrides these topological constraints, and “switches on” gene expression. Here, the topological constraint to IEG expression under basal conditions is represented as an open switch that is tethered by intact DNA. Formation of the break severs the constraint and promotes the circuit to be closed. The “brain bulb” represents the manifestation of neuronal activity.

sponse gene expression by preventing enhancer-promoter interactions, and this constraint is overcome through the formation of DSBs, which stimulates enhancer-promoter interactions at early response genes (Fig. 2). Recent observations indicate that a combination of enhancer elements interacts with the promoters of early response genes in a stimulus-dependent manner to drive their expression (Joo et al., 2016). Furthermore, neuronal stimulation causes widespread transcription at enhancer elements in neurons, resulting in the production of a class of noncoding RNAs called enhancer RNAs (Kim et al., 2010). Upon neuronal stimulation, these enhancer RNAs bind and inhibit NELF, a factor that maintains RNAPII in a paused state at the promoters of early response genes (Schaukowitch et al., 2014). Together, these studies could explain how topological architecture of the genome allows for the fine-tuning of gene expression in response to neuronal activity.

While DSB formation and their timely repair by the DSB repair machinery govern the dynamics of early response genes, a recent report demonstrated how late response genes, such as *Bdnf*, are regulated through active demethylation that requires the use of the base-excision repair pathway (Yu et al., 2015). The utilization of such strategies to regulate the expression of crucial activity-dependent genes in neurons has important pathophysiological implications. Defects in DNA repair have been linked to various congenital and age-related neurological disorders (Madabhushi et al., 2014). The unexpected link between DNA lesions and activity-induced gene expression suggests that changes in the ability to either form or repair activity-induced DNA lesions could have a huge impact on cognitive performance. Interestingly, in a recent report, homozygous mutations in the gene *TDP2* were discovered in patients with a neurological disease characterized by seizures, cognitive deficits, and ataxia (Gómez-Herrereros et al., 2014).

TDP2 encodes for the enzyme, tyrosyl-DNA phosphodiesterase 2 (TDP2), which specializes in the error-free repair of Topo II-mediated DSBs. Understanding whether neurological abnormalities caused by mutations in DNA repair factors, including TDP2, arise from the defective repair of activity-induced DSBs will therefore be of enormous significance.

In conclusion, here we review current efforts in understanding how readers, writers, and erasers of DNA methylation, the polycomb repressive complex, and DNA DSBs, coordinate the epigenetic changes that occur in response to neuronal activity. Future discoveries in these areas should provide a more refined understanding of how epigenetic mechanisms regulate crucial neuronal functions, such as synaptic plasticity and learning behaviors, and how dysregulation of these processes underlies developmental and neurodegenerative disorders.

References

- Abraham WC, Bear MF (1996) Metaplasticity: the plasticity of synaptic plasticity. *Trends Neurosci* 19:126–130. [CrossRef Medline](#)
- Amir RE, Van den Veyver IB, Wan M, Tran CQ, Francke U, Zoghbi HY (1999) Rett syndrome is caused by mutations in X-linked MECP2, encoding methyl-CpG-binding protein 2. *Nat Genet* 23:185–188. [CrossRef Medline](#)
- Barski A, Cuddapah S, Cui K, Roh TY, Schones DE, Wang Z, Wei G, Chepelev I, Zhao K (2007) High-resolution profiling of histone methylations in the human genome. *Cell* 129:823–837. [CrossRef Medline](#)
- Bird A (2002) DNA methylation patterns and epigenetic memory. *Genes Dev* 16:6–21. [CrossRef Medline](#)
- Bird A (2007) Perceptions of epigenetics. *Nature* 447:396–398. [CrossRef Medline](#)
- Bjornsson HT (2015) The Mendelian disorders of the epigenetic machinery. *Genome Res* 25:1473–1481. [CrossRef Medline](#)
- Brown KE, Guest SS, Smale ST, Hahm K, Merckenschlager M, Fisher AG (1997) Association of transcriptionally silent genes with Ikaros complexes at centromeric heterochromatin. *Cell* 91:845–854. [CrossRef Medline](#)
- Bunch H, Lawney BP, Lin YF, Asaithamby A, Murshid A, Wang YE, Chen BP, Calderwood SK (2015) Transcriptional elongation requires DNA break-induced signalling. *Nat Commun* 6:10191. [CrossRef Medline](#)
- Chahrouh M, Jung SY, Shaw C, Zhou X, Wong ST, Qin J, Zoghbi HY (2008) MeCP2, a key contributor to neurological disease, activates and represses transcription. *Science* 320:1224–1229. [CrossRef Medline](#)
- Chen L, Chen K, Lavery LA, Baker SA, Shaw CA, Li W, Zoghbi HY (2015) MeCP2 binds to non-CG methylated DNA as neurons mature, influencing transcription and the timing of onset for Rett syndrome. *Proc Natl Acad Sci U S A* 112:5509–5514. [CrossRef Medline](#)
- Cobos I, Long JE, Thwin MT, Rubenstein JL (2006) Cellular patterns of transcription factor expression in developing cortical interneurons. *Cereb Cortex* 16 [Suppl 1]:i82–i88.
- Collins AL, Levenson JM, Vilaythong AP, Richman R, Armstrong DL, Noebels JL, Sweatt DJ, Zoghbi HY (2004) Mild overexpression of MeCP2 causes a progressive neurological disorder in mice. *Hum Mol Genet* 13:2679–2689. [CrossRef Medline](#)
- Corley M, Kroll KL (2015) The roles and regulation of Polycomb complexes in neural development. *Cell Tissue Res* 359:65–85. [CrossRef Medline](#)
- Deneris ES, Hobert O (2014) Maintenance of postmitotic neuronal cell identity. *Nat Neurosci* 17:899–907. [CrossRef Medline](#)
- Di Meglio T, Kratochwil CF, Vilain N, Loche A, Vitobello A, Yonehara K, Hrycaj SM, Roska B, Peters AH, Eichmann A, Wellik D, Ducret S, Rijli FM (2013) Ezh2 orchestrates topographic migration and connectivity of mouse precerebellar neurons. *Science* 339:204–207. [CrossRef Medline](#)
- Dobenecker MW, Kim JK, Marcello J, Fang TC, Prinjha R, Bosselut R, Tarakhovskiy A (2015) Coupling of T cell receptor specificity to natural killer T cell development by bivalent histone H3 methylation. *J Exp Med* 212:297–306. [CrossRef Medline](#)
- Dong X, Tsuji J, Labadorf A, Roussos P, Chen JF, Myers RH, Akbarian S, Weng Z (2015) The role of H3K4me3 in transcriptional regulation is altered in Huntington's disease. *PLoS One* 10:e0144398. [CrossRef Medline](#)
- Feng J, Zhou Y, Campbell SL, Le T, Li E, Sweatt JD, Silva AJ, Fan G (2010) Dnmt1 and Dnmt3a maintain DNA methylation and regulate synaptic function in adult forebrain neurons. *Nat Neurosci* 13:423–430. [CrossRef Medline](#)
- Feng J, Shao N, Szulwach KE, Vialou V, Huynh J, Zhong C, Le T, Ferguson D, Cahill ME, Li Y, Koo JW, Ribeiro E, Labonte B, Laitman BM, Estey D, Stockman V, Kennedy P, Couroussé T, Mensah I, Turecki G, et al. (2015) Role of Tet1 and 5-hydroxymethylcytosine in cocaine action. *Nat Neurosci* 18:536–544. [CrossRef Medline](#)
- Francis NJ, Kingston RE (2001) Mechanisms of transcriptional memory. *Nat Rev Mol Cell Biol* 2:409–421. [CrossRef Medline](#)
- Gabel HW, Kinde B, Stroud H, Gilbert CS, Harmin DA, Kastan NR, Hemberg M, Ebert DH, Greenberg ME (2015) Disruption of DNA-methylation-dependent long gene repression in Rett syndrome. *Nature* 522:89–93. [CrossRef Medline](#)
- Gómez-Herrerros F, Schuurs-Hoeijmakers JH, McCormack M, Grealley MT, Rulten S, Romero-Granados R, Counihan TJ, Chaila E, Conroy J, Ennis S, Delanty N, Cortés-Ledesma F, de Brouwer AP, Cavalleri GL, El-Khamisy SF, de Vries BB, Caldecott KW (2014) TDP2 protects transcription from abortive topoisomerase activity and is required for normal neural function. *Nat Genet* 46:516–521. [CrossRef Medline](#)
- Greig LC, Woodworth MB, Galazo MJ, Padmanabhan H, Macklis JD (2013) Molecular logic of neocortical projection neuron specification, development and diversity. *Nat Rev Neurosci* 14:755–769. [CrossRef Medline](#)
- Guo JU, Su Y, Zhong C, Ming GL, Song H (2011a) Emerging roles of TET proteins and 5-hydroxymethylcytosines in active DNA demethylation and beyond. *Cell Cycle* 10:2662–2668. [CrossRef Medline](#)
- Guo JU, Su Y, Zhong C, Ming GL, Song H (2011b) Hydroxylation of 5-methylcytosine by TET1 promotes active DNA demethylation in the adult brain. *Cell* 145:423–434. [CrossRef Medline](#)
- Guo JU, Ma DK, Mo H, Ball MP, Jang MH, Bonaguidi MA, Balazer JA, Eaves HL, Xie B, Ford E, Zhang K, Ming GL, Gao Y, Song H (2011c) Neuronal activity modifies the DNA methylation landscape in the adult brain. *Nat Neurosci* 14:1345–1351. [CrossRef Medline](#)
- Guo JU, Su Y, Shin JH, Shin J, Li H, Xie B, Zhong C, Hu S, Le T, Fan G, Zhu H, Chang Q, Gao Y, Ming GL, Song H (2014) Distribution, recognition and regulation of non-CpG methylation in the adult mammalian brain. *Nat Neurosci* 17:215–222. [CrossRef Medline](#)
- Guy J, Gan J, Selfridge J, Cobb S, Bird A (2007) Reversal of neurological defects in a mouse model of Rett syndrome. *Science* 315:1143–1147. [CrossRef Medline](#)
- Hirabayashi Y, Suzuki N, Tsuboi M, Endo TA, Toyoda T, Shinga J, Koseki H, Vidal M, Gotoh Y (2009) Polycomb limits the neurogenic competence of neural precursor cells to promote astrogenic fate transition. *Neuron* 63:600–613. [CrossRef Medline](#)
- Hobert O (2011) Regulation of terminal differentiation programs in the nervous system. *Annu Rev Cell Dev Biol* 27:681–696. [CrossRef Medline](#)
- Hobert O (2016) A map of terminal regulators of neuronal identity in *Caenorhabditis elegans*. *Wiley Interdiscip Rev Dev Biol* 5:474–498. [CrossRef Medline](#)
- Ito S, D'Alessio AC, Taranova OV, Hong K, Sowers LC, Zhang Y (2010) Role of Tet proteins in 5mC to 5hmC conversion, ES-cell self-renewal and inner cell mass specification. *Nature* 466:1129–1133. [CrossRef Medline](#)
- Jaenisch R, Bird A (2003) Epigenetic regulation of gene expression: how the genome integrates intrinsic and environmental signals. *Nat Genet* 33 [Suppl]:245–254.
- Jenuwein T, Allis CD (2001) Translating the histone code. *Science* 293:1074–1080. [CrossRef Medline](#)
- Joo JY, Schaukowitz K, Farbiak L, Kilaru G, Kim TK (2016) Stimulus-specific combinatorial functionality of neuronal c-fos enhancers. *Nat Neurosci* 19:75–83. [CrossRef Medline](#)
- Ju BG, Lunyak VV, Perissi V, Garcia-Bassets I, Rose DW, Glass CK, Rosenfeld MG (2006) A topoisomerase IIbeta-mediated dsDNA break required for regulated transcription. *Science* 312:1798–1802. [CrossRef Medline](#)
- Kaas GA, Zhong C, Eason DE, Ross DL, Vachhani RV, Ming GL, King JR, Song H, Sweatt JD (2013) TET1 controls CNS 5-methylcytosine hydroxylation, active DNA demethylation, gene transcription, and memory formation. *Neuron* 79:1086–1093. [CrossRef Medline](#)
- Kandel ER (2001) The molecular biology of memory storage: a dialogue between genes and synapses. *Science* 294:1030–1038. [CrossRef Medline](#)
- Kim TK, Hemberg M, Gray JM, Costa AM, Bear DM, Wu J, Harmin DA, Laptewicz M, Barbara-Haley K, Kuersten S, Markenscoff-Papadimitriou E, Kuhl D, Bito H, Worley PF, Kreiman G, Greenberg ME (2010) Wide-

- spread transcription at neuronal activity-regulated enhancers. *Nature* 465:182–187. [CrossRef Medline](#)
- Kriaucionis S, Heintz N (2009) The nuclear DNA base 5-hydroxymethylcytosine is present in Purkinje neurons and the brain. *Science* 324:929–930. [CrossRef Medline](#)
- Li Y, Wang H, Muffat J, Cheng AW, Orlando DA, Lovén J, Kwok SM, Feldman DA, Bateup HS, Gao Q, Hockemeyer D, Mitalipova M, Lewis CA, Vander Heiden MG, Sur M, Young RA, Jaenisch R (2013) Global transcriptional and translational repression in human-embryonic-stem-cell-derived Rett syndrome neurons. *Cell Stem Cell* 13:446–458. [CrossRef Medline](#)
- Lister R, Mukamel EA, Nery JR, Urich M, Puddifoot CA, Johnson ND, Lucero J, Huang Y, Dwork AJ, Schultz MD, Yu M, Tonti-Filippini J, Heyn H, Hu S, Wu JC, Rao A, Esteller M, He C, Haghghi FG, Sejnowski TJ, et al. (2013) Global epigenomic reconfiguration during mammalian brain development. *Science* 341:1237905. [CrossRef Medline](#)
- Luikenhuis S, Giacometti E, Beard CF, Jaenisch R (2004) Expression of MeCP2 in postmitotic neurons rescues Rett syndrome in mice. *Proc Natl Acad Sci U S A* 101:6033–6038. [CrossRef Medline](#)
- Lyst MJ, Bird A (2015) Rett syndrome: a complex disorder with simple roots. *Nat Rev Genet* 16:261–275. [CrossRef Medline](#)
- Lyst MJ, Ekiert R, Ebert DH, Merusi C, Nowak J, Selfridge J, Guy J, Kastan NR, Robinson ND, de Lima Alves F, Rappasilber J, Greenberg ME, Bird A (2013) Rett syndrome mutations abolish the interaction of MeCP2 with the NCoR/SMRT co-repressor. *Nat Neurosci* 16:898–902. [CrossRef Medline](#)
- Ma DK, Jang MH, Guo JU, Kitabatake Y, Chang ML, Pow-Anpongkul N, Flavell RA, Lu B, Ming GL, Song H (2009) Neuronal activity-induced Gadd45b promotes epigenetic DNA demethylation and adult neurogenesis. *Science* 323:1074–1077. [CrossRef Medline](#)
- Madabhushi R, Pan L, Tsai LH (2014) DNA damage and its links to neurodegeneration. *Neuron* 83:266–282. [CrossRef Medline](#)
- Madabhushi R, Gao F, Pfenning AR, Pan L, Yamakawa S, Seo J, Rueda R, Phan TX, Yamakawa H, Pao PC, Stott RT, Gjonneska E, Nott A, Cho S, Kellis M, Tsai LH (2015) Activity-induced DNA breaks govern the expression of neuronal early-response genes. *Cell* 161:1592–1605. [CrossRef Medline](#)
- Mahy NL, Perry PE, Gilchrist S, Baldock RA, Bickmore WA (2002) Spatial organization of active and inactive genes and noncoding DNA within chromosome territories. *J Cell Biol* 157:579–589. [CrossRef Medline](#)
- Martinowich K, Hattori D, Wu H, Fouse S, He F, Hu Y, Fan G, Sun YE (2003) DNA methylation-related chromatin remodeling in activity-dependent BDNF gene regulation. *Science* 302:890–893. [CrossRef Medline](#)
- Meadows JP, Guzman-Karlsson MC, Phillips S, Holleman C, Posey JL, Day JJ, Hablitz JJ, Sweatt JD (2015) DNA methylation regulates neuronal glutamatergic synaptic scaling. *Sci Signal* 8:ra61. [CrossRef Medline](#)
- Mellén M, Ayata P, Dewell S, Kriaucionis S, Heintz N (2012) MeCP2 binds to 5hmC enriched within active genes and accessible chromatin in the nervous system. *Cell* 151:1417–1430. [CrossRef Medline](#)
- Miller CA, Sweatt JD (2007) Covalent modification of DNA regulates memory formation. *Neuron* 53:857–869. [CrossRef Medline](#)
- Mo A, Mukamel EA, Davis FP, Luo C, Henry GL, Picard S, Urich MA, Nery JR, Sejnowski TJ, Lister R, Eddy SR, Ecker JR, Nathans J (2015) Epigenomic signatures of neuronal diversity in the mammalian brain. *Neuron* 86:1369–1384. [CrossRef Medline](#)
- Mohn F, Weber M, Rebhan M, Roloff TC, Richter J, Stadler MB, Bibel M, Schübeler D (2008) Lineage-specific polycomb targets and de novo DNA methylation define restriction and potential of neuronal progenitors. *Mol Cell* 30:755–766. [CrossRef Medline](#)
- Molyneux BJ, Arlotta P, Menezes JR, Macklis JD (2007) Neuronal subtype specification in the cerebral cortex. *Nat Rev Neurosci* 8:427–437. [CrossRef Medline](#)
- Müller J, Hart CM, Francis NJ, Vargas ML, Sengupta A, Wild B, Miller EL, O'Connor MB, Kingston RE, Simon JA (2002) Histone methyltransferase activity of a *Drosophila* Polycomb group repressor complex. *Cell* 111:197–208. [CrossRef Medline](#)
- Nan X, Meehan RR, Bird A (1993) Dissection of the methyl-CpG binding domain from the chromosomal protein MeCP2. *Nucleic Acids Res* 21:4886–4892. [CrossRef Medline](#)
- Nan X, Campoy FJ, Bird A (1997) MeCP2 is a transcriptional repressor with abundant binding sites in genomic chromatin. *Cell* 88:471–481. [CrossRef Medline](#)
- Nan X, Ng HH, Johnson CA, Laherty CD, Turner BM, Eisenman RN, Bird A (1998) Transcriptional repression by the methyl-CpG-binding protein MeCP2 involves a histone deacetylase complex. *Nature* 393:386–389. [CrossRef Medline](#)
- Nelson ED, Kavalali ET, Monteggia LM (2008) Activity-dependent suppression of miniature neurotransmission through the regulation of DNA methylation. *J Neurosci* 28:395–406. [CrossRef Medline](#)
- Ooi SK, Bestor TH (2008) The colorful history of active DNA demethylation. *Cell* 133:1145–1148. [CrossRef Medline](#)
- Pereira JD, Sansom SN, Smith J, Dobenecker MW, Tarakhovskiy A, Livesey FJ (2010) Ezh2, the histone methyltransferase of PRC2, regulates the balance between self-renewal and differentiation in the cerebral cortex. *Proc Natl Acad Sci U S A* 107:15957–15962. [CrossRef Medline](#)
- Reynolds JP, Miller-Delaney SF, Jimenez-Mateos EM, Sano T, McKiernan RC, Simon RP, Henshall DC (2015) Transcriptional response of polycomb group genes to status epilepticus in mice is modified by prior exposure to epileptic preconditioning. *Front Neurol* 6:46. [CrossRef Medline](#)
- Rudenko A, Dawlaty MM, Seo J, Cheng AW, Meng J, Le T, Faull KF, Jaenisch R, Tsai LH (2013) Tet1 is critical for neuronal activity-regulated gene expression and memory extinction. *Neuron* 79:1109–1122. [CrossRef Medline](#)
- Schaukowitz K, Joo JY, Liu X, Watts JK, Martinez C, Kim TK (2014) Enhancer RNA facilitates NELF release from immediate early genes. *Mol Cell* 56:29–42. [CrossRef Medline](#)
- Seong IS, Woda JM, Song JJ, Lloret A, Abeyrathne PD, Woo CJ, Gregory G, Lee JM, Wheeler VC, Walz T, Kingston RE, Gusella JF, Conlon RA, MacDonald ME (2010) Huntingtin facilitates polycomb repressive complex 2. *Hum Mol Genet* 19:573–583. [CrossRef Medline](#)
- Shin J, Ming GL, Song H (2014) Decoding neural transcriptomes and epigenomes via high-throughput sequencing. *Nat Neurosci* 17:1463–1475. [CrossRef Medline](#)
- Skene PJ, Illingworth RS, Webb S, Kerr AR, James KD, Turner DJ, Andrews R, Bird AP (2010) Neuronal MeCP2 is expressed at near histone-octamer levels and globally alters the chromatin state. *Mol Cell* 37:457–468. [CrossRef Medline](#)
- Suberbielle E, Sanchez PE, Kravitz AV, Wang X, Ho K, Eilertson K, Devidze N, Kreitzer AC, Mucke L (2013) Physiologic brain activity causes DNA double-strand breaks in neurons, with exacerbation by amyloid-beta. *Nat Neurosci* 16:613–621. [CrossRef Medline](#)
- Sztainberg Y, Chen HM, Swann JW, Hao S, Tang B, Wu Z, Tang J, Wan YW, Liu Z, Rigo F, Zoghbi HY (2015) Reversal of phenotypes in MECP2 duplication mice using genetic rescue or antisense oligonucleotides. *Nature* 528:123–126. [CrossRef Medline](#)
- Tahiliani M, Koh KP, Shen Y, Pastor WA, Bandukwala H, Brudno Y, Agarwal S, Iyer LM, Liu DR, Aravind L, Rao A (2009) Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1. *Science* 324:930–935. [CrossRef Medline](#)
- Turrigiano GG (2008) The self-tuning neuron: synaptic scaling of excitatory synapses. *Cell* 135:422–435. [CrossRef Medline](#)
- Vaistij FE, Jones L, Baulcombe DC (2002) Spreading of RNA targeting and DNA methylation in RNA silencing requires transcription of the target gene and a putative RNA-dependent RNA polymerase. *Plant Cell* 14:857–867. [CrossRef Medline](#)
- Valinluck V, Tsai HH, Rogstad DK, Burdzy A, Bird A, Sowers LC (2004) Oxidative damage to methyl-CpG sequences inhibits the binding of the methyl-CpG binding domain (MBD) of methyl-CpG binding protein 2 (MeCP2). *Nucleic Acids Res* 32:4100–4108. [CrossRef Medline](#)
- Volpe TA, Kidner C, Hall IM, Teng G, Grewal SI, Martienssen RA (2002) Regulation of heterochromatic silencing and histone H3 lysine-9 methylation by RNAi. *Science* 297:1833–1837. [CrossRef Medline](#)
- von Schimmelmann M, Feinberg P, Sullivan J, Ku S, Badimon A, Duff M, Wang Z, Lachmann A, Dewell S, Ma'ayan A, Han M, Tarakhovskiy A, Schaefer A (2016) Polycomb repressive complex 2 (PRC2) silences genes responsible for neurodegeneration. *Nat Neurosci*. Advance online publication. doi: 10.1038/nn.4360. [CrossRef Medline](#)
- West AE, Greenberg ME (2011) Neuronal activity-regulated gene transcription in synapse development and cognitive function. *Cold Spring Harb Perspect Biol* 3:6. [CrossRef Medline](#)
- Wong RH, Chang I, Hudak CS, Hyun S, Kwan HY, Sul HS (2009) A role of DNA-PK for the metabolic gene regulation in response to insulin. *Cell* 136:1056–1072. [CrossRef Medline](#)
- Wu H, Zhang Y (2014) Reversing DNA methylation: mechanisms, genomics, and biological functions. *Cell* 156:45–68. [CrossRef Medline](#)
- Wu TP, Wang T, Seetin MG, Lai Y, Zhu S, Lin K, Liu Y, Byrum SD, Mackin-

- tosh SG, Zhong M, Tackett A, Wang G, Hon LS, Fang G, Swenberg JA, Xiao AZ (2016) DNA methylation on N(6)-adenine in mammalian embryonic stem cells. *Nature* 532:329–333. [CrossRef Medline](#)
- Yao B, Christian KM, He C, Jin P, Ming GL, Song H (2016) Epigenetic mechanisms in neurogenesis. *Nat Rev Neurosci* 17:537–549. [CrossRef Medline](#)
- Yazdani M, Deogracias R, Guy J, Poot RA, Bird A, Barde YA (2012) Disease modeling using embryonic stem cells: MeCP2 regulates nuclear size and RNA synthesis in neurons. *Stem Cells* 30:2128–2139. [CrossRef Medline](#)
- Yu H, Su Y, Shin J, Zhong C, Guo JU, Weng YL, Gao F, Geschwind DH, Coppola G, Ming GL, Song H (2015) Tet3 regulates synaptic transmission and homeostatic plasticity via DNA oxidation and repair. *Nat Neurosci* 18:836–843. [CrossRef Medline](#)
- Zabel C, Mao L, Woodman B, Rohe M, Wacker MA, Kläre Y, Koppelstätter A, Nebrich G, Klein O, Grams S, Strand A, Luthi-Carter R, Hartl D, Klose J, Bates GP (2009) A large number of protein expression changes occur early in life and precede phenotype onset in a mouse model for huntington disease. *Mol Cell Proteomics* 8:720–734. [CrossRef Medline](#)
- Zemke M, Draganova K, Klug A, Schöler A, Zurkirchen L, Gay MH, Cheng P, Koseki H, Valenta T, Schübeler D, Basler K, Sommer L (2015) Loss of Ezh2 promotes a midbrain-to-forebrain identity switch by direct gene derepression and Wnt-dependent regulation. *BMC Biol* 13:103. [CrossRef Medline](#)
- Zhang RR, Cui QY, Murai K, Lim YC, Smith ZD, Jin S, Ye P, Rosa L, Lee YK, Wu HP, Liu W, Xu ZM, Yang L, Ding YQ, Tang F, Meissner A, Ding C, Shi Y, Xu GL (2013) Tet1 regulates adult hippocampal neurogenesis and cognition. *Cell Stem Cell* 13:237–245. [CrossRef Medline](#)